Multiple Sclerosis and Cancer (P1.119)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To investigate the prevalence of cancer in multiple sclerosis (MS) patients and to compare cancer prevalence in patients on disease modifying therapy (DMT) versus those who were DMT naive. Background: Few studies have studied whether MS alters the risk of cancer, with varying results. Previous studies suggest that the use of DMT does not increase the risk of cancer, however these studies did not investigate the use of long term DMT use and subsequent cancer risk. Method: Subjects were part of the New York State Multiple Sclerosis Consortium (NYSMSC) registry. Cancer prevalence and DMT use was determined at study enrollment. Independent samples t-tests and chi-square tests were utilized to determine if there were any differences between those who had cancer compared to those who did not. A binomial test was used to determine if the prevalence of cancer in our sample was significantly different from the North American cancer prevalence of 3.2[percnt] as reported by the National Cancer Institute (NCI). Results: Of the 9,240 subjects in our study, 133 (1.4[percnt]) reported having cancer. Those who had cancer were older (51.8±11.2) than those who did not (43.7±11.2, p<.001) and had a later age at MS symptom onset compared to those who did not have cancer (38.6±12.1 vs 32.6±9.9, p<.001). Furthermore, MS patients with cancer were more likely to be female (84.2[percnt] vs 74.2[percnt], p=.009). There were no difference in DMT use between those who had cancer and those who did not. Conclusions: Results show that cancer prevalence in our sample of patients with MS was lower than reported by the NCI (p<.001). There were no significant differences in prevalence between those using a DMT and those who did not. We are in the process of collecting more information about type of cancer, specifics on medication use, and family history.
Disclosure: Dr. Gaindh has nothing to disclose. Dr. Kavak has nothing to disclose. Dr. Teter has received research support from Biogen Idec, Teva Neuroscience, EMD Serono, Avanir Pharmaceuticals, Novartis, and Genzyme Corporation. Dr. Nadeem has nothing to disclose. Dr. Weinstock-Guttman has received personal compensation for activities with Biogen Idec, Teva Neuroscience, EMD Serono, Pfizer Inc., Novartis, Genzyme Corporation, Sanofi-Aventis Pharmaceuticals, Inc., Mylan, and Acorda Therapeutics. Dr. Weinstock-Guttma
Monday, April 20 2015, 2:00 pm-6:30 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.